Grufity logo
Grufity logo

Latest Birchview Capital, LP Stock Portfolio

$175Million– No. of Holdings #73

Birchview Capital, LP Performance:
2026 Q1: 3.63%YTD: 3.63%2025: 10.92%
Performance for 2026 Q1 is 3.63%, and YTD is 3.63%, and 2025 is 10.92%.

About Birchview Capital, LP and 13F Hedge Fund Stock Holdings

On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Birchview Capital, LP reported an equity portfolio of $175.7 Millions as of 31 Mar, 2026.

The top stock holdings of Birchview Capital, LP are KLAC, BMY, CMPX. The fund has invested 16.7% of it's portfolio in KLA CORPORATION and 10.6% of portfolio in BRISTOL-MYERS SQUIBB CO.

The fund managers got completely rid off AMICUS THERAPEUTICS INC (FOLD), MASIMO CORP (MASI) and 10X GENOMICS INC (TXG) stocks. They significantly reduced their stock positions in PHREESIA INC (PHR), GOSSAMER BIO INC (GOSS) and CASTLE BIOSCIENCES INC (CSTL). Birchview Capital, LP opened new stock positions in RELMADA THERAPEUTICS INC (RLMD), OCULAR THERAPEUTIX INC (OCUL) and CELLDEX THERAPEUTICS INC (CLDX). The fund showed a lot of confidence in some stocks as they added substantially to UNIQURE NV (QURE), PACIFIC BIOSCIENCES OF CALIFORNIA INC (PACB) and UNITED THERAPEUTICS CORP (UTHR).
Birchview Capital, LP Equity Portfolio Value
Last Reported on: 15 May, 2026

Birchview Capital, LP Annual Return Estimates Vs S&P 500

Our best estimate is that Birchview Capital, LP made a return of 3.63% in the last quarter. In trailing 12 months, it's portfolio return was 19.81%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
relmada therapeutics inc2,849,330
ocular therapeutix inc2,710,400
celldex therapeutics inc2,223,410
compass pathways ltd2,073,750
engene holdings inc1,702,500
zenas biopharma inc1,368,500
biogen inc916,650
lipocine inc893,170
New stocks bought by Birchview Capital, LP

Additions

Ticker% Inc.
uniqure nv227
pacific biosciences of california inc200
united therapeutics corp50.00
intellia therapeutics inc41.22
novocure ltd33.02
quidelortho corp13.78
structure therapeutics inc11.11
zentalis pharmaceuticals inc2.96
Additions to existing portfolio by Birchview Capital, LP

Reductions

Ticker% Reduced
phreesia inc-87.08
gossamer bio inc-86.85
castle biosciences inc-84.00
immunome inc-61.54
apogee therapeutics inc-43.75
elutia inc-37.23
protagonist therapeutics inc-36.36
travere therapeutics inc-32.09
Birchview Capital, LP reduced stake in above stock

Sold off

Ticker$ Sold
amicus therapeutics inc-3,602,720
treace medical concepts inc-556,020
ventyx biosciences inc-910,468
biohaven ltd-670,231
10x genomics inc-962,290
alphatec holdings inc-379,940
rapt therapeutics inc-508,050
liquidia technologies inc-344,900
Birchview Capital, LP got rid off the above stocks

Sector Distribution

Birchview Capital, LP has about 67.5% of it's holdings in Healthcare sector.

  • Healthcare
  • Technology
  • Others
  • Energy
Sector%
Healthcare67.5
Technology21
Others5.8
Energy4.9

Market Cap. Distribution

Birchview Capital, LP has about 41.8% of it's portfolio invested in the large-cap and mega-cap stocks.

  • LARGE-CAP
  • SMALL-CAP
  • MID-CAP
  • UNALLOCATED
  • MICRO-CAP
  • MEGA-CAP
Category%
LARGE-CAP37.4
SMALL-CAP34.7
MID-CAP12.4
UNALLOCATED5.7
MICRO-CAP4.8
MEGA-CAP4.4

Stocks belong to which Index?

About 70.1% of the stocks held by Birchview Capital, LP either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • S&P 500
  • Others
Index%
RUSSELL 200036.1
S&P 50034
Others29.9
Top 5 Winners (%)%
BDSX
biodesix inc
113.2 %
ZNTL
zentalis pharmaceuticals inc
71.5 %
NKTR
nektar therapeutics
70.2 %
APLS
apellis pharmaceuticals inc
60.1 %
OVV
ovintiv inc
51.5 %
Top 5 Winners ($)$
KLAC
kla corporation
5.4 M
BDSX
biodesix inc
2.2 M
OVV
ovintiv inc
2.2 M
BMY
bristol-myers squibb co
2.0 M
LRCX
lam research corporation
1.6 M
Top 5 Losers (%)%
GOSS
gossamer bio inc
-50.6 %
LUNG
pulmonx corp
-41.6 %
QDEL
quidelortho corp
-41.0 %
OLMA
olema pharmaceuticals inc
-36.6 %
BCYC
bicycle therapeutics plc
-34.4 %
Top 5 Losers ($)$
OLMA
olema pharmaceuticals inc
-2.5 M
structure therapeutics inc
-2.0 M
BCYC
bicycle therapeutics plc
-1.1 M
PHAT
phathom pharmaceuticals inc
-1.1 M
QDEL
quidelortho corp
-0.9 M

Birchview Capital, LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Birchview Capital, LP

Birchview Capital, LP has 73 stocks in it's portfolio. About 54.6% of the portfolio is in top 10 stocks. OLMA proved to be the most loss making stock for the portfolio. KLAC was the most profitable stock for Birchview Capital, LP last quarter.

Last Reported on: 15 May, 2026
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions